RESUMO
One of the biggest challenges in treating depression is the heterogeneous and qualitative nature of its clinical presentations. This highlights the need to find quantitative molecular markers to tailor existing treatment strategies to the individual's biological system. In this study, high-resolution metabolic phenotyping of urine and plasma samples from the CAN-BIND study collected before treatment with two common pharmacological strategies, escitalopram and aripiprazole, was performed. Here we show that a panel of LDL and HDL subfractions were negatively correlated with depression in males. For treatment response, lower baseline concentrations of apolipoprotein A1 and HDL were predictive of escitalopram response in males, while higher baseline concentrations of apolipoprotein A2, HDL and VLDL subfractions were predictive of aripiprazole response in females. These findings support the potential of metabolomics in precision medicine and the possibility of identifying personalized interventions for depression.
Assuntos
Depressão/metabolismo , Adulto , Apolipoproteína A-I/sangue , Apolipoproteína A-I/urina , Apolipoproteína A-II/sangue , Apolipoproteína A-II/urina , HDL-Colesterol/sangue , HDL-Colesterol/urina , LDL-Colesterol/sangue , LDL-Colesterol/urina , VLDL-Colesterol/sangue , VLDL-Colesterol/urina , Depressão/diagnóstico , Feminino , Humanos , Masculino , Metaboloma , Pessoa de Meia-Idade , Plasma/química , Fatores Sexuais , Urina/química , Adulto JovemRESUMO
There exists a close relationship between cardiovascular diseases and chronic kidney disease. Apolipoprotein A1 and high-density lipoprotein (HDL) cholesterol are widely used as cardiovascular risk markers but they also have anti-inflammatory properties. The aim of this study was to investigate any associations between HDL levels and cytokine levels in urine. We randomly selected 90 urine samples from the Prospective Investigation of the Vasculature in Uppsala Seniors Study (41 males and 49 females). The samples were analyzed with 2 multiplex assays, Multiplex Inflammation I and Cardiovascular II kits (Olink Bioscience, Uppsala, Sweden). We analyzed the correlations between 158 cytokines in urine with apolipoprotein A1, HDL cholesterol, apolipoprotein B, and low-density lipoprotein cholesterol. There were strong correlations for apolipoprotein A1 and HDL cholesterol with individual cytokines. After adjustment for multiplicity testing, there were 33 significant correlations between apolipoprotein A1 and cytokine levels and 14 of these were also significantly correlated with HDL cholesterol. The strongest associations were observed for IL-1α, SPON2, RAGE, PAR-1, TRAIL-R2, IL-4RA, TNFRSF11A, and SCF. A total of 28 out of 33 correlations were negative, indicating a negative relationship between apolipoprotein A1 and urinary cytokines. The study shows a negative correlation between apolipoprotein A1 and HDL cholesterol and urinary cytokine levels. The finding is in agreement with the anti-inflammatory properties of HDL.
Assuntos
Apolipoproteína A-I/urina , HDL-Colesterol/urina , Citocinas/urina , Idoso , Feminino , Humanos , Masculino , Estudos ProspectivosRESUMO
Antecedentes. HDL es cuantitativamente la lipoproteína más importante en la mayoría de las especies y la evidencia mecanicista sugiere que HDL tendría un papel en la función inmunológica normal. Probamos la hipótesis que sugiere que las concentraciones plasmáticas de HDL están asociadas con el riesgo de enfermedades autoinmunes. Métodos. Se incluyeron 107.954 y 9.387 individuos con mediciones basales de colesterol-HDL provenientes de 2 estudios de la población general: el Estudio de la Población General de Copenhague y el Estudio del Corazón de Copenhague. Los pacientes fueron seguidos mediante el Registro Nacional Danés de pacientes desde el inicio del período 2003-2015 o 1991-1994 hasta 2017, tiempo durante el cual 4.078 y 1.101 individuos desarrollaron enfermedad autoinmune en los 2 estudios respectivamente. Resultados. En el Estudio de la Población General de Copenhague, en comparación a los individuos con colesterol de HDL =2,0 mmol/L (77 mg/dL), los índices de riesgo para cualquier enfermedad autoinmune, ajustados de manera multifactorial fueron 1,06 (IC 95%, 0,94-1,19) para individuos con colesterol-HDL entre 1,5 y 1,99 mmol/L (58 a 77 mg/dL), 1,18 (IC 95%, 1,04-1,35) para individuos con colesterol-HDL entre 1,0 y 1,49 mmol/L (39 a 58 mg/dL) y 1,84 (IC 95%, 1,52- 2,22) para individuos con colesterol-HDL <1,0 mmol/L (39 mg/dL) (p<0,001 para tendencia). Estos resultados fueron similares cuando: se excluyeron los eventos dentro de los 5 años del inicio del estudio, tanto en mujeres como hombres por separado, eventos en el inicio del estudio, independientemente de la inflamación de bajo grado o concentraciones de triglicéridos, para diferentes niveles de apolipoproteína A1 y para definiciones de punto final más restrictivas. Finalmente, el Estudio del Corazón de Copenhague proporcionó una confirmación independiente. Conclusiones: Los bajos niveles de colesterol-HDL se asocian con un alto riesgo de enfermedad autoinmune en individuos de la población general. Nuestros hallazgos observacionales no pueden determinar la causalidad.
Background. HDL is quantitatively the most important lipoprotein in most species and mechanistic evidence points toward a role for HDL in normal immune function. We tested the hypothesis that concentrations of HDL cholesterol are associated with risk of autoimmune disease. Methods. From 2 studies of the general population-the Copenhagen General Population Study and the Copenhagen City Heart study-we included 107,954 and 9,387 individuals with baseline measurements of HDL cholesterol. These were followed with the national Danish Patient Registry from baseline in 2003-2015 or 1991-1994 through 2017, during which time 4078 and 1101 individuals developed autoimmune disease in the 2 studies. Results. In the Copenhagen General Population Study, compared to individuals with HDL cholesterol =2.0 mmol/L (77 mg/dL), the multifactorially adjusted hazard ratios for any autoimmune disease were 1.06 (95% CI, 0.94-1.19) for individuals with HDL cholesterol of 1.5-1.99 mmol/L (58-77 mg/dL), 1.18 (95% CI, 1.04-1.35) for individuals with HDL cholesterol of 1.0-1.49 mmol/L (39-58 mg/dL), and 1.84 (95% CI, 1.52-2.22) for individuals with HDL cholesterol <1.0 mmol/L (39 mg/dL) (p for trend <0.001). These results were similar when excluding events within 5 years of baseline, in women and men separately, for events at baseline, irrespective of low-grade inflammation or triglyceride concentrations, for the apolipoprotein A1 part of HDL, and for more restrictive end point definitions. Finally, the Copenhagen City Heart Study provided independent confirmation. Conclusions. Low HDL cholesterol level is associated with high risk of autoimmune disease in individuals from the general population. Our observational findings cannot determine causality.
Assuntos
Humanos , Masculino , Feminino , Pessoa de Meia-Idade , Idoso , Doenças Autoimunes/diagnóstico , HDL-Colesterol/sangue , Doenças Autoimunes/sangue , Estudos Epidemiológicos , Dinamarca , HDL-Colesterol/urinaRESUMO
PURPOSE: We studied the health benefits of low calorie cranberry beverage consumption on glucoregulation, oxidative damage, inflammation, and lipid metabolism in overweight but otherwise healthy humans. METHODS: 78 overweight or obese men and women (30-70 years; BMI 27-35 kg/m2) with abdominal adiposity (waist: hip > 0.8 for women and > 0.9 for men; waist: height ≥ 0.5) consumed 450 mL placebo or low calorie, high polyphenol cranberry extract beverage (CEB) daily for 8 week in a randomized, double-blind, placebo-controlled, parallel design trial. Blood and urine samples were collected after overnight fast at baseline and after 8 weeks of daily beverage consumption. Blood and urine samples were also collected during 3 oral glucose tolerance test (OGTT) challenges: (1) pre-intervention without the test beverages, (2) following a single dose of placebo or CEB at baseline (week 0), and (3) following a single dose of placebo or CEB at 8 week. RESULTS: Compared to placebo, a single CEB dose at baseline lowered endothelin-1 and elevated nitric oxide and the reduced:oxidized glutathione ratio (P < 0.05). Interferon-γ was elevated (P < 0.05) after a single CEB dose at baseline; however, after 8 week of CEB intervention, fasting C-reactive protein was lower (P < 0.05). CEB consumption for 8 week also reduced serum insulin and increased HDL cholesterol compared to placebo (P < 0.05). CONCLUSIONS: An acute dose of low calorie, high polyphenol cranberry beverage improved antioxidant status, while 8 week daily consumption reduced cardiovascular disease risk factors by improving glucoregulation, downregulating inflammatory biomarkers, and increasing HDL cholesterol.
Assuntos
Bebidas , HDL-Colesterol/efeitos dos fármacos , Inflamação/prevenção & controle , Sobrepeso/metabolismo , Polifenóis/farmacologia , Vaccinium macrocarpon , Adulto , Idoso , Biomarcadores/sangue , Biomarcadores/urina , HDL-Colesterol/sangue , HDL-Colesterol/urina , Método Duplo-Cego , Feminino , Glucose/metabolismo , Teste de Tolerância a Glucose , Humanos , Metabolismo dos Lipídeos/efeitos dos fármacos , Masculino , Pessoa de Meia-Idade , Sobrepeso/sangue , Sobrepeso/urina , Estresse Oxidativo/efeitos dos fármacos , Extratos Vegetais/administração & dosagem , Extratos Vegetais/farmacologia , Polifenóis/administração & dosagemRESUMO
A significant inverse relationship between the 24-hour urine pH and number of metabolic syndrome (MS) features(BMI ≥ 30 kg/m2, circumference > 88cm, HDL-cholesterol < 50mg/dL, etc.) was identified in individuals, which means that 24-hour urine pH values decrease with an increasing number of MS features. In this respect, we examined the association between the number of MS features and spot urine pH instead of 24-hour urine pH. A positive relationship was observed between the spot urine pH and number of MS features by analysis of covariance, with the age, gender, and eGFR as covariates. On the other hand, a high level of serum uric acid (UA) indicated a significantly lower spot urine pH compared with a normal level of UA. Serum UA was a significant independent variable explaining the decrease of the urine pH. The results of path analysis showed that UA had negative effects on the number of MS features and urine pH. Therefore, a positive relationship between the number of MS features and urine pH will be a spurious correlation with UA as a confounding factor. In addition, the negative relationship between the number of MS features and UA was also a spurious correlation with age as a confounding factor. From these results, the serum UA level should be considered to evaluate the relationship between the number of MS features and spot urine pH.
Assuntos
HDL-Colesterol/urina , Síndrome Metabólica/diagnóstico , Ácido Úrico/sangue , Ácido Úrico/urina , HDL-Colesterol/sangue , Humanos , Concentração de Íons de Hidrogênio , Síndrome Metabólica/sangue , Síndrome Metabólica/urina , Valor Preditivo dos Testes , Fatores de RiscoRESUMO
We describe a child with acute post-streptococcal glomerulonephritis (APSGN), who developed a very low plasma high-density lipoprotein cholesterol (α-lipoprotein) in association with transient but massive proteinuria. The hypoalphalipoproteinaemia resolved spontaneously concomitant with the remission in proteinuria and the patient had a complete clinical recovery. Urinary loss of apolipoprotein A1 may have contributed to the hypoalphalipoproteinaemia. To our knowledge, this has not been reported previously in APSGN.
Assuntos
HDL-Colesterol/metabolismo , Glomerulonefrite/etiologia , Infecções Estreptocócicas/diagnóstico , Doença Aguda , Antibacterianos/uso terapêutico , Pré-Escolar , HDL-Colesterol/urina , Seguimentos , Glomerulonefrite/fisiopatologia , Glomerulonefrite/terapia , Humanos , Masculino , Proteinúria/etiologia , Proteinúria/fisiopatologia , Doenças Raras , Medição de Risco , Índice de Gravidade de Doença , Infecções Estreptocócicas/complicações , Infecções Estreptocócicas/tratamento farmacológico , Resultado do TratamentoRESUMO
Few studies have addressed the delivery of lipoprotein-derived cholesterol to the adrenals for steroid production in humans. While there is evidence against a role for low-density lipoprotein (LDL), it is unresolved whether high density lipoprotein (HDL) contributes to adrenal steroidogenesis. To study this, steroid hormone profiles in urine were assessed in male subjects suffering from functional mutations in ATP binding cassette transporter A1 (ABCA1) (n = 24), lecithin:cholesterol acyltransferase (LCAT) (n = 40), as well as in 11 subjects with low HDL cholesterol (HDL-C) without ABCA1/LCAT mutations. HDL-C levels were 39% lower in the ABCA1, LCAT, and low HDL-C groups compared with controls (all P < 0.001). In all groups with low HDL-C levels, urinary excretion of 17-ketogenic steroids was reduced by 33%, 27%, and 32% compared with controls (all P < 0.04). In seven carriers of either type of mutation, adrenocorticotropic hormone (ACTH) stimulation did not reveal differences from normolipidemic controls. In conclusion, this study shows that basal but not stimulated corticosteroid metabolism is attenuated in subjects with low HDL-C, irrespective of its molecular origin. These findings lend support to a role for HDL as a cholesterol donor for basal adrenal steroidogenesis in humans.
Assuntos
Glândulas Suprarrenais/metabolismo , HDL-Colesterol/sangue , Esteroides/biossíntese , Transportador 1 de Cassete de Ligação de ATP , Transportadores de Cassetes de Ligação de ATP/genética , Transportadores de Cassetes de Ligação de ATP/metabolismo , Hormônio Adrenocorticotrópico/sangue , Hormônio Adrenocorticotrópico/urina , Adulto , Idoso , HDL-Colesterol/urina , Humanos , Masculino , Pessoa de Meia-Idade , Fosfatidilcolina-Esterol O-Aciltransferase/genética , Fosfatidilcolina-Esterol O-Aciltransferase/metabolismo , Esteroides/urinaRESUMO
The objective was to study the lipoprotein levels in primary hyperuricaemic patients and to analyse their renal management or urates in order to check for some potential influence of altered lipid levels on the renal excretion of urates by this type of patient. Overall 115 male individuals were studied in five groups, namely: 30 primary hyperuricaemic (group I); 27 primary hyperuricaemic-hypercholesterolaemic (group II); nine primary hyperuricaemic-hypertriglyceridaemic (group III); 33 primary hyperuricaemic-mixed hyperlipidaemic (group IV); and 16 normouricaemic-normolipidaemic subjects (group C). All patients were subjected to blood analyses for uric acid, total triglycerides, total protein, creatinine, high density lipoprotein (HDL) cholesterol, very low density lipoprotein (VLDL) cholesterol, low density lipoprotein (LDL) cholesterol, apoprotein (apo) AI, apoprotein B, apoprotein CII and apoproteins CIII1 and CIII2. For urine analysis creatinine, creatinine clearance, uric acid excretion, clearance and fractional excretion were measured in 24 h urine samples. Mixed and pure hyperuricaemic-hypertriglyceridaemic patients exhibited increased levels of VLDL components, decreased fractional excretion of uric acid and increased apo CIII/CII ratios. The increased levels of structural VLDL components were negatively (and statistically significantly) correlated with the fractional excretion of uric acid; this suggests a close biological relationship between the two parameters. Taking into account the role played by apo C in VLDL metabolism, the altered apo CIII/CII ratios found in hyperuricaemic-hypertriglyceridaemic patients (both pure and mixed) suggest that this apoprotein plays a central role in the physiopathology of the alterations observed.
Assuntos
Hipertrigliceridemia/urina , Lipoproteínas VLDL/urina , Ácido Úrico/urina , Adulto , Apolipoproteínas B/sangue , Apolipoproteínas B/urina , HDL-Colesterol/sangue , HDL-Colesterol/urina , Humanos , Lipoproteínas VLDL/sangue , Masculino , Pessoa de Meia-Idade , Estatística como Assunto , Ácido Úrico/sangueRESUMO
The pathophysiological mechanisms resulting in hyperlipidaemia in albuminuric insulin-dependent diabetic patients are largely unknown. Increased non-specific hepatic protein synthesis as a response to urinary protein loss, has been proposed. However in that case it is unexplained why the plasma concentration of the high density lipoprotein (HDL) subfraction, in contrast to all other lipoprotein subfractions, is normal or even reduced in albuminuric patients. We studied the urinary excretion of HDL-cholesterol in 26 insulin-dependent diabetic patients matched according to sex and age into three groups. I: normal urinary albumin excretion (< 30 mg 24 h-1; n = 8); II: incipient nephropathy (urinary albumin excretion in the range of 30-300 mg 24 h-1; n = 7); and III: clinical nephropathy (urinary albumin excretion > 300 mg 24 h-1; n = 11). Eight normal subjects served as controls. Lipoproteins in urine were separated by ultracentrifugation, and the daily urinary loss of HDL-cholesterol was 1.30 mumol (0.83-2.21) (median and range) in controls, 1.27 mumol (0.56-2.59) in group I, 1.39 mumol (0.55-1.97) in group II and 4.02 mumol (1.33-42.12) in group III (p < 0.01). More than 95% of cholesterol in urine was found in the HDL-fraction. The plasma concentrations of total cholesterol, very low density lipoprotein cholesterol, low density lipoprotein cholesterol and triglyceride were 21-94% higher in patients with clinical nephropathy compared with normal controls and group I.(ABSTRACT TRUNCATED AT 250 WORDS)
Assuntos
Albuminúria/urina , HDL-Colesterol/urina , Diabetes Mellitus Tipo 1/urina , Nefropatias Diabéticas/urina , Adulto , Colesterol/sangue , Colesterol/urina , LDL-Colesterol/sangue , VLDL-Colesterol/sangue , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Triglicerídeos/sangueRESUMO
The effect of prazosin treatment on blood pressure, plasma HDL-cholesterol concentration, and apoprotein-AI/HDL (apoAI/HDL) kinetics was studied in 11 patients with mild hypertension. Blood pressure (mean +/- SEM) fell from 143 +/- 1/96 +/- 1 to 134 +/- 1/86 +/- 1 mm Hg after 4 to 5 months of prazosin treatment (P less than .001), associated with an increase in plasma HDL-cholesterol concentration from 38 +/- 2 to 46 +/- 2 mg/dL (P less than .001). Both the fractional catabolic rate (FCR) and total synthetic rate of apoAI/HDL, which were higher than previous reported values for normal individuals, decreased from 0.36 +/- 0.02 to 0.30 +/- 0.02 L/day and 17.4 +/- 1.1 to 13.8 +/- 1.1 mg/kg/min, respectively. These changes were statistically significant, and the post-treatment values for both variables were now within the normal range. When the decay curve was further analyzed by nonlinear curve fitting, it was shown that the return to normal of the FCR of apoAI/HDL in patients treated with prazosin was accounted for by the decrease of the decay constants of the second [p(2)] and third [p(3)] components of the 125I-AI/HDL disappearance curve. In conclusion, abnormalities in HDL concentration and HDL kinetics exist in patients with very mild hypertension. These defects were significantly improved with prazosin treatment, and this may render the compound of particular clinical benefit in the treatment of patients with mild hypertension.
Assuntos
Apolipoproteínas A/sangue , HDL-Colesterol/sangue , Hipertensão/sangue , Prazosina/farmacologia , Apolipoproteína A-I , Apolipoproteínas A/urina , Pressão Sanguínea/efeitos dos fármacos , HDL-Colesterol/urina , Esquema de Medicação , Avaliação de Medicamentos , Feminino , Humanos , Hipertensão/tratamento farmacológico , Hipertensão/urina , Insulina/sangue , Radioisótopos do Iodo , Masculino , Pessoa de Meia-Idade , Prazosina/administração & dosagem , Prazosina/uso terapêuticoRESUMO
The mechanism leading to hyperlipidemia in the nephrotic syndrome is not fully understood but may be related in part to loss of high density lipoproteins in the urine of patients with nephrosis. To prove this hypothesis, we compared serum lipoprotein profiles with the excretion of high density lipoproteins in urine in 19 nephrotic patients. Serum cholesterol ranged from 19-152 (median value 45) mg/dl in very low density lipoproteins (VLDL), from 130-443 (median 186) mg/dl in low density lipoproteins (LDL) and from 19-64 (median 33) mg/dl in high density lipoproteins (HDL). Hyperlipoproteinemia was found in 17 patients, which was classified as phenotype IIa (Fredrickson) in 2, as phenotype IIb in 9 and as phenotype IV in 6 subjects. Two patients showed normal lipoprotein patterns. VLDL- and LDL-cholesterol were not found in detectable amounts in urine, whereas HDL-cholesterol was measured in low concentrations from 0.1-8.3 mg/24 h in all samples. There was no correlation between serum HDL-cholesterol and urinary HDL-cholesterol, but a positive correlation between serum LDL-cholesterol and urinary HDL-cholesterol (r = +0.54, p less than 0.05). However, the total amount of the daily urinary loss of HDL (less than 1% of total plasma HDL) seems not to be sufficient to explain hyperlipoproteinemia in the nephrotic syndrome.